Compare Neurocrine Biosciences Inc (NBIX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nuscale Power Corporation — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Nuscale Power Corporation trades at $7.2 (market cap $3.00B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.8× Nuscale Power Corporation's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Nuscale Power Corporation for 29 Days on average.
| NBIX | SMR | |
|---|---|---|
Market Cap | $14.36B | $3.00B |
Volume | 1,237,180 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $185.50 | $53.43 |
52-Week Low | $123.10 | $7.20 |
Typical Hold Time | 23 Days | 29 Days |
Enterprise Value | $14.37B | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
NuScale Power (SMR) trades at $7.32, down 4.56% today, amid bearish technical signals and challenging fundamentals. The company reported significant losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Despite analyst consensus pointing to a $11.25 price target with 50% buy ratings, recent news highlights investor concerns including an ongoing legal investigation announced by Pomerantz Law Firm on October 1, 2026.
The stock faces substantial execution risks as it burns cash to commercialize small modular reactor technology. While nuclear energy presents long-term growth potential, SMR's path to profitability remains uncertain given current financial metrics and competitive pressures from established players like GE Vernova. The wide analyst target range ($6-$16) reflects divided sentiment on the company's prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
